Stem-cell therapy

Cell Therapy Market to Reach $48.11 Bn, Globally, by 2027 at 25.6% CAGR: Allied Market Research

Retrieved on: 
Monday, October 12, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Cell therapy, Kite Pharma, Stem-cell therapy

PORTLAND, Ore., Oct. 12, 2020 /PRNewswire/ --Allied Market Research published a report, titled," Cell Therapy Market " by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 20202027."

Key Points: 
  • PORTLAND, Ore., Oct. 12, 2020 /PRNewswire/ --Allied Market Research published a report, titled," Cell Therapy Market " by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 20202027."
  • Based on cell type, the stem cell segment contributed to nearly three-fifths of the global cell therapy market share in 2019 and is expected to retain its dominance by 2027.
  • Based on therapy type, the allogeneic segment accounted nearly three-fifths of the global cell therapy market revenue in 2019 and is anticipated to lead the trail from 2020 to 2027.
  • Based on region, North America generated the highest share in 2019, holding around half of the global cell therapy market.

Cell Therapy Market to Reach $48.11 Bn, Globally, by 2027 at 25.6% CAGR: Allied Market Research

Retrieved on: 
Monday, October 12, 2020
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Cell therapy, Kite Pharma, Stem-cell therapy

PORTLAND, Ore., Oct. 12, 2020 /PRNewswire/ --Allied Market Research published a report, titled," Cell Therapy Market " by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 20202027."

Key Points: 
  • PORTLAND, Ore., Oct. 12, 2020 /PRNewswire/ --Allied Market Research published a report, titled," Cell Therapy Market " by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 20202027."
  • Based on cell type, the stem cell segment contributed to nearly three-fifths of the global cell therapy market share in 2019 and is expected to retain its dominance by 2027.
  • Based on therapy type, the allogeneic segment accounted nearly three-fifths of the global cell therapy market revenue in 2019 and is anticipated to lead the trail from 2020 to 2027.
  • Based on region, North America generated the highest share in 2019, holding around half of the global cell therapy market.

BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa

Retrieved on: 
Monday, October 12, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Emerging technologies, Induced stem cells, Cell biology, Stem-cell therapy

NEW YORK, Oct. 12, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2020 Cell & Gene Meeting on the Mesa , being held virtually October 12-16, 2020.

Key Points: 
  • NEW YORK, Oct. 12, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2020 Cell & Gene Meeting on the Mesa , being held virtually October 12-16, 2020.
  • Dr. Lindborg's presentation will be in the form of an on-demand webinar that will be available beginning today.
  • At the conclusion of the 2020 Cell & Gene Meeting on the Mesa, a copy of the presentation will also be available in the "Investors and Media" section of the BrainStorm website under Events and Presentations .
  • BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

NDA Partners Expert Consultant Ellen Areman, Receives AABB Award for Major Contributions to the Field of Cellular Therapies

Retrieved on: 
Wednesday, October 7, 2020
Branches of biology, Articles, Biology, Stem cells, Biotechnology, Cell biology, Induced stem cells, AABB, Stem-cell therapy, Transfusion medicine, Consultant

The award recognizes an individual who has demonstrated teaching ability and has made a major contribution to the field of transfusion medicine or cellular therapies.

Key Points: 
  • The award recognizes an individual who has demonstrated teaching ability and has made a major contribution to the field of transfusion medicine or cellular therapies.
  • She joined NDA Partners as an Expert Consultant in 2015 and provides regulatory strategy and CMC support to companies developing biological products including hematopoietic, immunologic, and stem cell therapies.
  • She is a member of AABB and a founding member of the International Society for Cell Therapies.
  • Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

RenovaCare Elects Alan L. Rubino to Chairman of the Board of Directors

Retrieved on: 
Monday, October 5, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Life extension, Stem-cell therapy

Mr. Rubino replaces Harmel S. Rayat as Chairman of the Board, who resigned from the Board and as Chairman on the same date.

Key Points: 
  • Mr. Rubino replaces Harmel S. Rayat as Chairman of the Board, who resigned from the Board and as Chairman on the same date.
  • We wish Mr. Rayat continued success in his future business endeavors, concluded Mr. Rubino.
  • RenovaCare, Inc. is developing first-of-its-kind autologous (self-donated) stem cell therapies for the regeneration of human organs.
  • RenovaCare is developing its CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars.

BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Corporate Update

Retrieved on: 
Friday, October 2, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Developmental biology, Cell biology, Mesenchymal stem cell, Adult stem cell, Cellular differentiation, Induced stem cells, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs).
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Primary Cells Market worth $1,613 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, October 1, 2020
Branches of biology, Biology, Life sciences, Stem cells, Immunology, Biotechnology, Immune system, T cell, Cell biology, Induced stem cells, Stem-cell therapy

Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the Primary Cells Market.

Key Points: 
  • Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the Primary Cells Market.
  • The human primary cells segment accounted for the largest share of the Primary Cells Market, by origin segment, in 2019
    Based on origin, the Primary Cells Market is segmented into human and animal primary cells.
  • The human primary cells segment accounted for the largest share in the Primary Cells Market in 2019.
  • Based on type, the Primary Cells Market is segmented into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells.

Primary Cells Market worth $1,613 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, October 1, 2020
Branches of biology, Biology, Life sciences, Stem cells, Immunology, Biotechnology, Immune system, T cell, Cell biology, Induced stem cells, Stem-cell therapy

Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the Primary Cells Market.

Key Points: 
  • Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the Primary Cells Market.
  • The human primary cells segment accounted for the largest share of the Primary Cells Market, by origin segment, in 2019
    Based on origin, the Primary Cells Market is segmented into human and animal primary cells.
  • The human primary cells segment accounted for the largest share in the Primary Cells Market in 2019.
  • Based on type, the Primary Cells Market is segmented into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells.

BAYLX, INC. Receives US FDA Clearance of COVID-19 IND Application For Umbilical Cord Tissue Mesenchymal Stem Cells Product

Retrieved on: 
Wednesday, September 30, 2020
Research, Infectious diseases, FDA, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Science, Life sciences, Biology, Branches of biology, Biotechnology, Stem cells, Mesenchymal stem cell, Investigational New Drug, Biopharmaceutical, Mesoblast, Stem-cell therapy

Baylx, Inc. (Baylx), a clinical-stage stem cell biopharmaceutical company focused on developing living stem cell products to address unmet medical needs, announced that the U.S. Food and Drug Administration (FDA) has cleared Baylx's Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with COVID-19.

Key Points: 
  • Baylx, Inc. (Baylx), a clinical-stage stem cell biopharmaceutical company focused on developing living stem cell products to address unmet medical needs, announced that the U.S. Food and Drug Administration (FDA) has cleared Baylx's Investigational New Drug (IND) application for BX-U001, a fresh, non-frozen human umbilical cord tissue mesenchymal stem cells (hUC-MSC) product in patients with COVID-19.
  • Mesenchymal stem cells hold great promise to treat COVID-19 patients due to their potential in inhibiting the overactivated immune system and promoting the recovery of pulmonary and other organs failure in severe COVID-19 cases.
  • This is Baylxs second IND clearance from FDA in three months.
  • In early June this year, Baylx also received the clearance of an IND from US FDA for the same product, BX-U001, in the treatment of rheumatoid arthritis (RA).

Regenerative Medicine Market worth $17.9 billion by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, September 30, 2020
Branches of biology, Biology, Articles, Emerging technologies, Stem cells, Regenerative biomedicine, Induced stem cells, Biotechnology, Regenerative medicine, Stem-cell therapy

The tissue-engineered products segment accounted for the largest share of the Regenerative Medicine Market, by product segment, in 2019

Key Points: 
  • The tissue-engineered products segment accounted for the largest share of the Regenerative Medicine Market, by product segment, in 2019
    Based on products, the market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies.
  • The tissue-engineered products segment accounted for the largest share in the market in 2019.
  • Based on applications, the Regenerative Medicine Market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications.
  • Get 10% Customization Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65442579
    The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).